Nanjing Vazyme Biotech Co Ltd Total Liabilities

Latest as of June 2026: CN¥1.03 Billion CNY ≈ $150.58 Million USD

Nanjing Vazyme Biotech Co Ltd total liabilities. Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has total liabilities worth CN¥1.03 Billion CNY (≈ $150.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Nanjing Vazyme Biotech Co Ltd's assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Nanjing Vazyme Biotech Co Ltd (2017–2025)

Total liabilities of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025. This chart illustrates how Nanjing Vazyme Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data.

Nanjing Vazyme Biotech Co Ltd Competitors by Total Liabilities

The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Tangshan Sanyou Chemical Industries Co Ltd
SHG:600409
China CN¥11.24 Billion
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
China CN¥7.18 Billion
PC Connection Inc
NASDAQ:CNXN
USA $503.33 Million
CoCreation Grass Co Ltd
SHG:605099
China CN¥837.51 Million
Chang Wah Technology Co Ltd
TWO:6548
Taiwan NT$13.17 Billion
A.F.P. Provida
SN:PROVIDA
Chile CL$206.75 Billion
Kemper Corporation
NYSE:KMPR
USA $9.75 Billion
RAPT Therapeutics Inc
NASDAQ:RAPT
USA $13.76 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Nanjing Vazyme Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 688105 current and non-current assets.

Liquidity & Leverage Metrics

Nanjing Vazyme Biotech Co Ltd Total Liabilities Ratios Explained

Nanjing Vazyme Biotech Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.99 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.29 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nanjing Vazyme Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nanjing Vazyme Biotech Co Ltd (2017–2025)

The table below shows the annual total liabilities of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥1.24 Billion
≈ $180.97 Million
+11.92%
2024-12-31 CN¥1.11 Billion
≈ $161.70 Million
-35.64%
2023-12-31 CN¥1.72 Billion
≈ $251.24 Million
+23.24%
2022-12-31 CN¥1.39 Billion
≈ $203.85 Million
+190.33%
2021-12-31 CN¥479.83 Million
≈ $70.21 Million
+71.81%
2020-12-31 CN¥279.28 Million
≈ $40.87 Million
+124.65%
2019-12-31 CN¥124.31 Million
≈ $18.19 Million
+46.82%
2018-12-31 CN¥84.67 Million
≈ $12.39 Million
+125.34%
2017-12-31 CN¥37.57 Million
≈ $5.50 Million
--

About Nanjing Vazyme Biotech Co Ltd

SHG:688105 China Biotechnology
Market Cap
$1.68 Billion
CN¥11.49 Billion CNY
Market Cap Rank
#6532 Global
#1285 in China
Share Price
CN¥22.22
Change (1 day)
-7.03%
52-Week Range
CN¥13.14 - CN¥27.59
All Time High
CN¥119.29
About

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more